Kura Oncology (KURA) Other Operating Expenses (2014 - 2026)

Kura Oncology's (KURA) quarterly Other Operating Expenses came in at $262000.0 in Q1 2026, down 98.42% on a QoQ basis from $16.6 million in Q4 2018.

Kura Oncology (KURA) Other Operating Expenses (2014 - 2026) Analysis & Trends

Kura Oncology (KURA) has 6 years of Other Operating Expenses data on file, last reported at $262000.0 in Q1 2026.

On a quarterly basis, Other Operating Expenses changed N/A year-over-year to $262000.0 in Q1 2026; TTM through Mar 2026 was $262000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $57000.0, changed N/A from the prior year.
Other Operating Expenses for Q1 2026 stood at $262000.0, down from $16.6 million in the prior quarter.
Over the last five years, Other Operating Expenses for KURA reached as high as $262000.0 in Q1 2026 and fell as low as $262000.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-
10	Kura Oncology	928.19 Mn	928.19 Mn	18.00 Mn

Download Data